Hypersensitivity Myocarditis Following Deferasirox Administration

Circ Cardiovasc Imaging. 2022 Feb;15(2):e013702. doi: 10.1161/CIRCIMAGING.121.013702. Epub 2022 Jan 31.

Authors

Andrea Frustaci¹, Romina Verardo², Giancarlo Labbadia^{1

2}, Vito Menafra^{1

2}, Nicola Galea¹, Matteo Antonio Russo³

Affiliations

¹ Department of Cardiovascular, Respiratory, Nephrological, Anesthesiologic and Geriatric Sciences, Sapienza University, Rome, Italy (A.F., G.L., V.M., N.G.).
² Cellular and Molecular Cardiology Lab, IRCCS L. Spallanzani, Rome, Italy (R.V.).
³ MEBIC Consortium, San Raffaele University and IRCCS San Raffaele, Rome, Italy (M.A.R.).

PMID: 35094520
DOI: 10.1161/CIRCIMAGING.121.013702

No abstract available

Keywords: autopsy; biopsy; deferasirox; hypersensitivity; myocarditis.

Publication types

Case Reports
Research Support, Non-U.S. Gov't
Video-Audio Media

MeSH terms

Aged
Biopsy
Deferasirox / adverse effects*
Drug Hypersensitivity / diagnosis
Drug Hypersensitivity / etiology*
Echocardiography
Electrocardiography
Female
Humans
Iron Chelating Agents / adverse effects
Magnetic Resonance Imaging, Cine / methods
Myelodysplastic Syndromes / drug therapy
Myocarditis / chemically induced*
Myocarditis / diagnosis
Myocardium / pathology*

Substances

Iron Chelating Agents
Deferasirox